These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8622703)

  • 41. An activating mutation in the ATP binding site of the ABL kinase domain.
    Allen PB; Wiedemann LM
    J Biol Chem; 1996 Aug; 271(32):19585-91. PubMed ID: 8702653
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation.
    Chissoe SL; Bodenteich A; Wang YF; Wang YP; Burian D; Clifton SW; Crabtree J; Freeman A; Iyer K; Jian L
    Genomics; 1995 May; 27(1):67-82. PubMed ID: 7665185
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.
    Demiroglu A; Steer EJ; Heath C; Taylor K; Bentley M; Allen SL; Koduru P; Brody JP; Hawson G; Rodwell R; Doody ML; Carnicero F; Reiter A; Goldman JM; Melo JV; Cross NC
    Blood; 2001 Dec; 98(13):3778-83. PubMed ID: 11739186
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
    Carlesso N; Frank DA; Griffin JD
    J Exp Med; 1996 Mar; 183(3):811-20. PubMed ID: 8642285
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia.
    Melo JV; Gordon DE; Tuszynski A; Dhut S; Young BD; Goldman JM
    Blood; 1993 May; 81(10):2488-91. PubMed ID: 8490164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571.
    Beissert T; Puccetti E; Bianchini A; Güller S; Boehrer S; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
    Blood; 2003 Oct; 102(8):2985-93. PubMed ID: 12829585
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
    Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
    Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Bcr N-terminal oligomerization domain contributes to the full oncogenicity of P190 Bcr/Abl in transgenic mice.
    Heisterkamp N; Voncken JW; Senadheera D; Hemmeryckx B; Gonzalez-Gomez I; Reichert A; Pattengale PK; Groffen J
    Int J Mol Med; 2001 Apr; 7(4):351-7. PubMed ID: 11254872
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia.
    Diamond J; Goldman JM; Melo JV
    Blood; 1995 Apr; 85(8):2171-5. PubMed ID: 7718887
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protein kinase CK2alpha is a target for the Abl and Bcr-Abl tyrosine kinases.
    Hériché JK; Chambaz EM
    Oncogene; 1998 Jul; 17(1):13-8. PubMed ID: 9671309
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
    Carlesso N; Griffin JD; Druker BJ
    Oncogene; 1994 Jan; 9(1):149-56. PubMed ID: 8302574
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
    Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
    Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The function of BCR/ABL and related proto-oncogenes.
    Gotoh A; Broxmeyer HE
    Curr Opin Hematol; 1997 Jan; 4(1):3-11. PubMed ID: 9050373
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells.
    Naldini L; Stacchini A; Cirillo DM; Aglietta M; Gavosto F; Comoglio PM
    Mol Cell Biol; 1986 May; 6(5):1803-11. PubMed ID: 2431286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site.
    de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
    Oncogene; 1997 Feb; 14(5):507-13. PubMed ID: 9053848
    [TBL] [Abstract][Full Text] [Related]  

  • 56. C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis.
    Skorski T; Nieborowska-Skorska M; Szczylik C; Kanakaraj P; Perrotti D; Zon G; Gewirtz A; Perussia B; Calabretta B
    Cancer Res; 1995 Jun; 55(11):2275-8. PubMed ID: 7757976
    [TBL] [Abstract][Full Text] [Related]  

  • 57. p160 Bcr mediates platelet-derived growth factor activation of extracellular signal-regulated kinase in vascular smooth muscle cells.
    Che W; Abe J; Yoshizumi M; Huang Q; Glassman M; Ohta S; Melaragno MG; Poppa V; Yan C; Lerner-Marmarosh N; Zhang C; Wu Y; Arlinghaus R; Berk BC
    Circulation; 2001 Sep; 104(12):1399-406. PubMed ID: 11560856
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
    Nieborowska-Skorska M; Slupianek A; Skorski T
    Oncogene; 2000 Aug; 19(36):4117-24. PubMed ID: 10962572
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tyrosine phosphorylation enhances the SH2 domain-binding activity of Bcr and inhibits Bcr interaction with 14-3-3 proteins.
    Peters KL; Smithgall TE
    Cell Signal; 1999 Jul; 11(7):507-14. PubMed ID: 10405761
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
    Gishizky ML; Cortez D; Pendergast AM
    Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.